{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T19:04:28Z","timestamp":1789239868197,"version":"build-2803163510"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,11,1]],"date-time":"2021-11-01T00:00:00Z","timestamp":1635724800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008593","name":"European Respiratory Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000574","name":"British Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000574","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001465","name":"American Thoracic Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001465","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006259","name":"Teva Pharmaceutical Industries","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006259","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1016\/j.anai.2021.06.007","type":"journal-article","created":{"date-parts":[[2021,6,18]],"date-time":"2021-06-18T11:10:59Z","timestamp":1624014659000},"page":"548-552","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Impact of nasal polyps on endotype and phenotype in patients with moderate to severe asthma"],"prefix":"10.1016","volume":"127","author":[{"given":"Rory","family":"Chan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Lipworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10","key":"10.1016\/j.anai.2021.06.007_bib0001","doi-asserted-by":"crossref","first-page":"3363","DOI":"10.1016\/j.jaip.2020.06.048","article-title":"Pragmatic clinical perspective on biologics for severe refractory type 2 asthma","volume":"8","author":"Chan","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"12","key":"10.1016\/j.anai.2021.06.007_bib0002","doi-asserted-by":"crossref","first-page":"2312","DOI":"10.1111\/all.13875","article-title":"EUFOREA consensus on biologics for CRSwNP with or without asthma","volume":"74","author":"Fokkens","year":"2019","journal-title":"Allergy"},{"issue":"3","key":"10.1016\/j.anai.2021.06.007_bib0003","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1111\/all.13342","article-title":"RItA: the Italian severe\/uncontrolled asthma registry","volume":"73","author":"Maio","year":"2018","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2021.06.007_bib0004","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1111\/all.13489","article-title":"Th2 cytokines orchestrate the secretion of MUC5AC and MUC5B in IL-5-positive chronic rhinosinusitis with nasal polyps","volume":"74","author":"Zhang","year":"2019","journal-title":"Allergy"},{"issue":"suppl S29","key":"10.1016\/j.anai.2021.06.007_bib0005","first-page":"1","article-title":"European position paper on rhinosinusitis and nasal polyps 2020","volume":"58","author":"Fokkens","year":"2020","journal-title":"Rhinology"},{"issue":"3","key":"10.1016\/j.anai.2021.06.007_bib0006","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.jaci.2020.05.032","article-title":"Efficacy and safety of omalizumab in nasal polyposis: 2 randomized phase 3 trials","volume":"146","author":"Gevaert","year":"2020","journal-title":"J Allergy Clin Immunol"},{"issue":"10209","key":"10.1016\/j.anai.2021.06.007_bib0007","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1016\/S0140-6736(19)31881-1","article-title":"Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials","volume":"394","author":"Bachert","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.anai.2021.06.007_bib0008","doi-asserted-by":"crossref","first-page":"2461","DOI":"10.1016\/j.jaip.2021.01.031","article-title":"Indirect treatment comparison of biologics in chronic rhinosinusitis with nasal polyps","volume":"9","author":"Peters","year":"2021","journal-title":"J Allergy Clin Immunol Pract"},{"key":"10.1016\/j.anai.2021.06.007_bib0009","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.rmed.2019.04.017","article-title":"Association between exhaled nitric oxide and nasal polyposis in severe asthma","volume":"152","author":"Maniscalco","year":"2019","journal-title":"Respir Med"},{"key":"10.1016\/j.anai.2021.06.007_bib0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1186\/s13223-019-0388-4","article-title":"Does unified allergic airway disease impact on lung function and type 2 biomarkers?","volume":"15","author":"Kuo","year":"2019","journal-title":"Allergy Asthma Clin Immunol"},{"issue":"12","key":"10.1016\/j.anai.2021.06.007_bib0011","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1111\/cea.13747","article-title":"Impaired small airway function in non-asthmatic chronic rhinosinusitis with nasal polyps","volume":"50","author":"Du","year":"2020","journal-title":"Clin Exp Allergy"},{"issue":"8","key":"10.1016\/j.anai.2021.06.007_bib0012","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS recommendations for standardized procedures for the online and offline measurement of exhaled lower respiratory nitric oxide and nasal nitric oxide, 2005","volume":"171","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.anai.2021.06.007_bib0013","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.anai.2021.06.007_bib0014","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1183\/09031936.03.00089403","article-title":"The forced oscillation technique in clinical practice: methodology, recommendations and future developments","volume":"22","author":"Oostveen","year":"2003","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2021.06.007_bib0015","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jaci.2015.12.1336","article-title":"Utility of impulse oscillometry in patients with moderate to severe persistent asthma","volume":"138","author":"Jabbal","year":"2016","journal-title":"J Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2021.06.007_bib0016","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S2213-2600(19)30049-9","article-title":"Exploring the relevance and extent of small airways dysfunction in asthma (ATLANTIS): baseline data from a prospective cohort study","volume":"7","author":"Postma","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.anai.2021.06.007_bib0017","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1164\/rccm.201812-2322OC","article-title":"Lung computational models and the role of the small airways in asthma","volume":"200","author":"Foy","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2021.06.007_bib0018","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s00408-019-00247-y","article-title":"I say IOS you say AOS: comparative bias in respiratory impedance measurements","volume":"197","author":"Kuo","year":"2019","journal-title":"Lung"},{"issue":"6","key":"10.1016\/j.anai.2021.06.007_bib0019","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1378\/chest.12-1310","article-title":"Inhaled corticosteroid dose response using domiciliary exhaled nitric oxide in persistent asthma: the FENOtype trial","volume":"142","author":"Anderson","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.anai.2021.06.007_bib0020","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1111\/cea.13310","article-title":"Variability of blood eosinophils in patients in a clinic for severe asthma","volume":"49","author":"Rakowski","year":"2019","journal-title":"Clin Exp Allergy"},{"issue":"4","key":"10.1016\/j.anai.2021.06.007_bib0021","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1016\/j.jaip.2016.12.027","article-title":"Clinical characteristics of patients with chronic rhinosinusitis with nasal polyps, asthma, and aspirin-exacerbated respiratory disease","volume":"5","author":"Stevens","year":"2017","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2021.06.007_bib0022","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.anai.2018.08.009","article-title":"Is small airways dysfunction related to asthma control and type 2 inflammation?","volume":"121","author":"Kuo","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"1","key":"10.1016\/j.anai.2021.06.007_bib0023","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.jaci.2010.08.042","article-title":"Use of the Asthma Control Questionnaire to predict future risk of asthma exacerbation","volume":"127","author":"Meltzer","year":"2011","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"10.1016\/j.anai.2021.06.007_bib0024","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1016\/j.jaci.2009.11.033","article-title":"Overall asthma control: the relationship between current control and future risk","volume":"125","author":"Bateman","year":"2010","journal-title":"J Allergy Clin Immunol"},{"issue":"7","key":"10.1016\/j.anai.2021.06.007_bib0025","doi-asserted-by":"crossref","first-page":"2462","DOI":"10.1016\/j.jaip.2019.03.044","article-title":"Dupilumab improves nasal polyp burden and asthma control in patients with CRSwNP and AERD","volume":"7","author":"Laidlaw","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"2","key":"10.1016\/j.anai.2021.06.007_bib0026","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01785-2017","article-title":"Predictors of accelerated decline in lung function in adult-onset asthma","volume":"51","author":"Coumou","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.anai.2021.06.007_bib0027","doi-asserted-by":"crossref","unstructured":"Chan R, RuiWen Kuo C, Lipworth B. Real-life small airway outcomes in severe asthma patients receiving biologic therapies [e-pub ahead of print]. J Allergy Clin Immunol Pract. doi: 10.1016\/j.jaip.2021.01.029, accessed May 14, 2021.","DOI":"10.1016\/j.jaip.2021.01.029"},{"issue":"26","key":"10.1016\/j.anai.2021.06.007_bib0028","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severeuncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N Engl J Med"},{"issue":"10056","key":"10.1016\/j.anai.2021.06.007_bib0029","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor \u03b1 monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.anai.2021.06.007_bib0030","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/cea.13057","article-title":"Blood eosinophils: the forgotten man of inhaled steroid dose titration","volume":"48","author":"Jabbal","year":"2018","journal-title":"Clin Exp Allergy"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621004476?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120621004476?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:26:50Z","timestamp":1761053210000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120621004476"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,11]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["S1081120621004476"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2021.06.007","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2021,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of nasal polyps on endotype and phenotype in patients with moderate to severe asthma","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2021.06.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}